The Company enters 2026 with Multiple Phase 2 Catalysts collectively representing ~$8 billion in potential market ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

HLP003 (previously referred to as CYB003): a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy ...

AI emerged as a key differentiator in accelerating development timelines and enhancing clinical operations. Decentralized ...

Over the past several years, pharmaceutical companies have been steadily integrating artificial intelligence (AI) into many aspects of clinical development. Today, AI’s impact is being felt from the ...

Planned SAD and MAD Studies Mark Key Clinical Inflection Point for Intranasal PTSD and Anxiety SARASOTA, FL, Dec. 30, 2025 (GLOBE NEWSWIRE) -- ...

OKYO Pharma Limited, a clinical-stage biopharmaceutical company listed on NASDAQ, reported clinical updates and interim financial results as of September 30, 2024. The company is developing OK-101, an ...

LONDON (Reuters) - Major drugmakers are using artificial intelligence to find patients for clinical trials quickly, or to reduce the number of people needed to test medicines, both accelerating drug ...

Medicus Pharma Ltd ( ($MDCX) ) just unveiled an update. Medicus Pharma will present at Biotech Showcase 2026 in San Francisco as it enters the ...

SAN FRANCISCO--(BUSINESS WIRE)--Circle Pharma, a biopharmaceutical company advancing the discovery and development of intrinsically cell-permeable macrocycles, announced today the selection of CID-078 ...

AI-guided, synthetic lethal therapy achieves complete metabolic response after just two cycles in patient who failed three prior state-of-the-art treatment regimens. Complete response in an aggressive ...